Author/Editor     Lainščak, Mitja; Laviano, Alessandro
Title     ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker
Type     članek
Vol. and No.     Letnik 7, št. 4
Publication year     2016
Volume     str. 400-402
ISSN     2190-5991 - Journal of cachexia, sarcopenia and muscle
Language     eng
Abstract     Novel action beta-blockers combine many different pharmacological effects. The espindolol exhibits effects through beta and central 5-HT1alpha receptors to demonstrate pro-anabolic, anti-catabolic, and appetite-stimulating actions. In the ACT-ONE trial, espindolol reversed weight loss and improved handgrip strength in patients with cachexia due to non-small cell lung cancer or colorectal cancer. With this trial, another frontier of cachexia management is in sight. Nonetheless, more efficacy and safety data is needed before new therapeutic indications for novel action beta-blockers can be endorsed.
Descriptors     Cachexia
Kaheksija
Adrenergic beta-Antagonists
Adrenergični beta antagonisti
Prevention and control
Preprečevanje in nadzor
Therapeutic use
Uporaba za zdravljenje